The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance

International Journal of Infectious Diseases

Volumn 16, Issue 6, 2012, Pages

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Yan, Bing Zhu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Insulin resistance; Metformin; Sustained virological response, SVR

Indexed keywords

METFORMIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADJUVANT THERAPY; ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HUMAN; HYPERLACTATEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84860362080     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.02.004     Document Type: Article

References (19)

1. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
2. Gao B., Hong F., Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004, 39:880-890.
3. Patton H.M., Patel K., Behling C., Bylund D., Blatt L.M., Vallee M., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
4. Lonardo A., Adinolfi L.E., Loria P., Carulli N., Ruggiero G., Day C.P. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-597.
5. Petit J.M., Bour J.B., Galland-Jos C., Minello A., Verges B., Guiguet M., et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001, 35:279-283.
6. Yu J.W., Li S.C., Wang G.Q. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006, 26:166-172.
7. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., Salmerón J., Diago M., Fernández-Rodríguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
8. Poustchi H., Negro F., Hui J., Cua I.H., Brandt L.R., Kench J.G., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
9. Bailey C.J., Path M.R., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
10. Romero-Gómez M., Diago M., Andrade R.J., Calleja J.L., Salmerón J., Fernández-Rodríguez C.M., et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-1708.
11. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
12. Khattab M., Emad M., Abdelaleem A., Eslam M., Atef R., Shaker Y., et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010, 30:447-454.
13. Pazienza V., Clément S., Pugnale P., Conzelman S., Foti M., Mangia A., et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
14. Holland W., Morrison T., Chang Y., Wiernsperger N., Stith B.J. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 2004, 67:2081-2091.
15. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25.
16. Serfaty L., Fartoux L., Poupon R. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?. J Hepatol 2009, 50:1269-1271.
17. Serfaty L. Pioglitazone: the beginning of a new era for NASH?. J Hepatol 2007, 47:160-162.
18. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
19. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.